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In practice




In recent years, nonmammographic breast imaging devices, such as 
thermography, electrical impedance scanning and elastography, have 
been promoted directly to consumers, which has captured the attention of 
governments, researchers and health organisations. These devices are not 
supported by evidence and risk undermining existing mammographic breast 
cancer screening services. 
During a 5-year period, Cancer Council Western Australia (CCWA) used 
strategic research combined with legal, policy and media advocacy to 
contest claims that these devices were proven alternatives to mammography 
for breast cancer screening. The campaign was successful because it 
had input from people with public health, academic, clinical and legal 
backgrounds, and took advantage of existing legal and regulatory avenues. 
CCWA’s experience provides a useful advocacy model for public health 
practitioners who are concerned about unsafe consumer products, unproven 
medical devices, and misleading health information and advertising.
Introduction
The promotion of emerging breast cancer imaging devices directly to 
consumers has generated increasing interest and concern internationally.1–3 
In 2010, Cancer Council Western Australia (CCWA) became aware of several 
commercial breast imaging companies in Perth, Western Australia, that 
were offering nonmammographic ‘screening’. CCWA identified at least three 
classes of devices being promoted: thermography, electrical impedance 
scanning and elastography. 
There is a paucity of scientific evidence supporting the efficacy of these 
devices for breast cancer screening4; however, if they are promoted directly 
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Key points
• Thermography, electrical impedance 
scanning and elastography are 
nonmammographic devices that have 
been promoted directly to consumers for 
breast cancer screening, despite a lack of 
evidence of efficacy
• Cancer Council Western Australia 
undertook strategic research, used media 
and policy advocacy, and engaged with 
the Australian Competition and Consumer 
Commission to investigate this issue
• In 2014, two breast imaging companies 
were found by the Federal Court of 
Australia to have engaged in misleading 
and deceptive conduct
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to women, they may be perceived as an alternative 
to mammography, and women might choose these 
companies and devices instead.5 At an individual level, 
women who are persuaded by misleading claims cannot 
give fully informed consent, are subject to ineffective 
tests and, if a lesion exists, risk a delayed breast cancer 
diagnosis. False positive and false negative results 
have considerable negative psychological and practical 
consequences for many women. 
At a population level, the unregulated growth of 
alternative breast imaging services may cause confusion, 
and undermine consumer confidence and participation 
in publicly funded breast cancer screening programs, 
such as BreastScreen WA. There is also a clear potential 
for these companies to increase the burden on the 
healthcare system by referring women for unnecessary 
further investigations.
CCWA is Western Australia’s biggest cancer charity. 
Its mission is to “work with [the] community to reduce the 
incidence and the impact of cancer”, with a commitment 
to making a real difference.6 Specifically, this includes 
advocating for and supporting existing publicly funded, 
evidence based programs such as BreastScreen 
and the National Bowel Cancer Screening Program.7 
CCWA works closely with these and other like-minded 
agencies to improve participation by the target group in 
appropriate screening.
This paper looks back at each step in a series of 
advocacy activities led by CCWA, which culminated in 
a successful outcome and were intended to protect the 
public from the potential harms associated with unproven 
breast imaging. It was not planned as a campaign; 
however, it had several of the characteristics of a 
comprehensive advocacy campaign.
Gathering the evidence
The initial stage of the project investigated the level and 
quality of evidence surrounding the devices. The National 
Health and Medical Research Council found “no evidence 
of sufficient quality to demonstrate thermography is 
effective for early detection or screening for breast 
cancer”.8 This position is supported by recent systematic 
reviews of the literature on thermography, electrical 
impedance scanning and elastography, which found 
that there was not sufficient evidence to support their 
use for breast cancer screening or diagnosis.4,9,10 CCWA 
developed a consumer fact sheet on the evidence that 
was published on its website in 2010.11
CCWA then collaborated with BreastScreen WA and 
The University of Western Australia to produce a report on 
companies providing unproven breast imaging services 
in Western Australia.12 By March 2011, there were at least 
28 companies across Australia offering unproven breast 
imaging services, including in rural areas that may not 
have regular or immediate access to mammographic 
breast screening.13
In light of the paucity of evidence and the wide 
distribution of the companies, CCWA and Curtin 
University conducted intercept surveys with 300 women 
aged 25–54 (representing the target market) to assess 
the impact of breast imaging companies’ promotional 
materials on consumers’ beliefs about the technology. 
The surveys showed that 90% of respondents believed 
the advertised device was effective in detecting breast 
cancer, and 80% believed the advertised device was 
equally or more effective than a mammogram in detecting 
breast cancer.5 These results prompted CCWA to broaden 
and intensify its advocacy efforts.
Advocacy
Legal advocacy
Three legal avenues for redress in cases of suspected 
advertising misconduct were identified:
1. Law on the advertising of therapeutic goods
2. Law on the approval, listing and availability of 
therapeutic goods
3. Consumer protection law.
The Therapeutic Goods Administration (TGA) sits 
within the Australian Government Department of Health 
and regulates therapeutic goods in Australia – such as 
prescription medicines and medical devices – through 
the Australian Register of Therapeutic Goods (ARTG) 
and the Therapeutic Goods Advertising Code. CCWA 
raised a complaint to the TGA’s Complaints Resolution 
Panel (CRP) about a company making unsubstantiated 
claims about an electrical impedance device. CCWA also 
submitted incident reports to the TGA in an attempt to 
reduce the availability of the devices.
CCWA also raised the issue with the Australian 
Competition and Consumer Commission (ACCC), 
Australia’s consumer law watchdog. CCWA provided 
the ACCC with information as it conducted formal 
investigations, including observations on the nature and 
size of the industry in Western Australia and throughout 
the country.
Media advocacy
CCWA engaged with the media to raise awareness 
of potentially misleading claims. For example, a joint 
media statement between Cancer Council Australia (a 
CCWA affiliate), the ACCC and the TGA in June 2011 
urged women not to rely on unproven commercial breast 
imaging technologies to detect breast cancer.3
Policy advocacy
Advocacy was used to highlight government policies 
that had facilitated the growth of the commercial breast 
imaging industry and that had failed to ensure adequate 
oversight of marketing practices.
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A significant limitation of the TGA’s CRP is that it has 
no power to enforce its determinations. CCWA supports 
stronger powers for the CRP, including the ability to 
investigate and enforce, and to refer noncompliance to 
the ACCC, which has powers of enforcement. CCWA 
made submissions to consultations about the TGA held 
by the Department of Health and engaged with federal 
Senators from all major political parties on this issue.
CCWA made a submission in response to the 
Australian Health Ministers’ Advisory Council’s 
consultation paper on a national code of conduct for 
healthcare workers, including arguing for an enforceable, 
statutory code of conduct for unregistered healthcare 
workers – specifically, the inclusion of standard nine: 
“Health care workers not to misinform their clients”. This 
standard was included in the terms of a National Code 
of Conduct for healthcare workers endorsed by the 
Council of Australian Governments’ health ministers in 
April 2015.14
Impact 
In response to concerns raised by CCWA, the ACCC 
commenced legal proceedings against two companies 
in December 2011, alleging their marketing practices 
had been misleading or deceptive. At the time, at least 
28 companies were offering unproven breast imaging 
services in Australia. By March 20125: 
• Seven of these companies voluntarily ceased trading
• Two added a statement to their websites to clarify that 
their service was not a replacement for conventional 
breast imaging modalities
• Three removed the breast imaging material from their 
websites, effectively ceasing promotion of the service.
In March 2014, the Federal Court of Australia handed 
down judgements against the companies and their 
operators.15,16 Safe Breast Imaging Pty Ltd (SBI) used an 
electrical impedance device exclusively, whereas Breast 
Check Pty Ltd (BC) used various digital thermography 
devices in addition to electrical impedance scanning. The 
court found the companies had engaged in misleading 
and deceptive conduct in their promotional materials. 
Additionally, SBI had falsely claimed that a medical doctor 
was involved in the preparation of reports.
SBI, which operated across four Australian states, was 
fined $200 000, with its sole director receiving a penalty 
of $50 000. The director was also disqualified from 
managing a company for 4 years.17 BC’s contraventions 
were considered less serious and attracted a penalty of 
$75 000.18 The judgements and penalties have been such 
a strong deterrent that internet search engines for similar 
companies in Australia now return few results.
Additionally, the TGA removed some thermography 
and electrical impedance devices from the ARTG, 
because the companies promoting them were unable to 
substantiate claims about their ability to detect breast 
cancer with independent, peer-reviewed literature. 
CCWA’s complaints to the CRP did not lead to a 
determination and no further action was taken by the CRP, 
partly because of their lack of enforcement power. 
Discussion 
The marketing of thermography, electrical impedance 
scanning and elastography directly to consumers is of 
concern internationally because of a lack of independent, 
peer-reviewed literature to support the stand-alone use 
of these devices in breast cancer screening. By adopting 
a comprehensive legal, media and policy strategy, this 
campaign was able to contribute to a reduction in the 
number of Australian companies offering unproven breast 
imaging devices. 
This advocacy was initiated in a climate of intense 
scientific debate about mammographic breast cancer 
screening. It has been argued that such programs result 
in overdiagnosis and overtreatment, and that declines 
in breast cancer mortality can be ascribed mainly to 
improved treatments and breast cancer awareness.19 
Despite its limitations, mammography remains the gold 
standard for breast cancer screening and is estimated 
to provide a relative risk reduction for breast cancer 
mortality of 20%.20
Another challenge was staying apprised of 
developments in the industry in Western Australia, 
Australia and overseas. It was observed that websites 
and social media were the primary means by which 
unproven breast imaging companies promoted their 
services5, and that the services were often transitory. 
There was, and still is, a risk that new unproven 
devices will fill the gap left in the market after the 
successful campaign. Although this risk exists, the 
experience gained, evidence built and partnerships 
formed during this advocacy campaign will allow for a 
more rapid, efficient response to any emerging threats.
The mix of skills and organisations among those 
concerned about the impact of unproven breast cancer 
screening devices was critical to the success. Each 
step was guided by a highly experienced public health 
advocate at CCWA. At all times, however, there was 
a combination of public health skills and specialised 
skills relevant to the stage of the campaign. The 
evidence-gathering activities included experts in 
market research, health psychology, health technology 
assessment, breast cancer screening, and breast 
cancer diagnosis and treatment. The advocacy activities 
included team members with legal and public health 
advocacy expertise. 
Conclusion 
CCWA’s campaign provides a useful case study for public 
health professionals involved in advocacy and policy 
development. Like other advocacy case studies, however, 
it is difficult to draw a causal link between the campaign 
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and the outcomes achieved. Because of the nature of 
advocacy, outcomes lie outside the advocate’s control.21 
Although there is no definitive blueprint for a 
successful advocacy campaign, there are lessons that 
can be taken from this work. Although it did not start as a 
planned campaign, it is consistent with other successful 
public health advocacy campaigns in that it was iterative, 
based on sound evidence and drew on a range of 
advocacy strategies to work towards a desired outcome.21
Perhaps the most valuable and unusual aspects of 
this advocacy campaign were the mix of professional 
skills involved, the strong partnerships developed, 
and the strategic collection and use of data during a 
relatively short period of time. The credibility and authority 
provided by experts and organisations, combined with 
the contemporary, relevant evidence used in the early 
phases of the campaign, is likely to have contributed to 
its success. 
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